ADA and Alzheimer disease: Our observations correlate with recent studies showing deregulation of purine metabolism, manifested (1) as reduced 5’-NT activity, (2) as increased ADA in parietal (PC) and temporal cortex (TC), and (3) as reduced ATP generation, and compromised mitochondria, in both AD patients or AD mice [46–48].